111 related articles for article (PubMed ID: 2347055)
1. Ifosfamide combination chemotherapy in advanced breast cancer.
Schmid H; Kaufmann M; Grischke EM; Bastert G
Cancer Chemother Pharmacol; 1990; 26 Suppl():S71-3. PubMed ID: 2347055
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.
Manegold C; Worst P; Bickel J; Schmid H; Drings P; Kaufmann M
Cancer Chemother Pharmacol; 1990; 26 Suppl():S87-90. PubMed ID: 2112056
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
Langenbuch T; Mross K; Jonat W; Hossfeld DK
Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Ghavamzadeh A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S66-8. PubMed ID: 2347052
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.
Bellmunt J; Morales S; Navarro M; Solé LA
Cancer Chemother Pharmacol; 1990; 26 Suppl():S81-4. PubMed ID: 2347056
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
[TBL] [Abstract][Full Text] [Related]
7. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Gurney H; Harnett P; Stuart-Harris R; Kefford R
Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
[TBL] [Abstract][Full Text] [Related]
9. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.
Gad-el-Mawla N; Hamza MR; Zikri ZK; Elserafi M; el-Khodari A; Khaled H; Gafaar R
Cancer Chemother Pharmacol; 1990; 26 Suppl():S85-6. PubMed ID: 2347057
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Hoffmann W; Weidmann B; Migeod F; Könner J; Seeber S
Cancer Chemother Pharmacol; 1990; 26 Suppl():S69-70. PubMed ID: 2347053
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
[TBL] [Abstract][Full Text] [Related]
13. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Loeffler TM; Weber FW; Hausamen TU
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma].
Huang HQ; Zhou ZM; Li YH; Jiang WQ; He YJ; Teng XY; Guan ZZ
Ai Zheng; 2002 Apr; 21(4):409-11. PubMed ID: 12452022
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study.
Klaassen U; Harstrick A; Strumberg D; Wilke H; Seeber S
Anticancer Drugs; 1998 Apr; 9(4):359-61. PubMed ID: 9635927
[TBL] [Abstract][Full Text] [Related]
18. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Bunnell CA; Thompson L; Buswell L; Berkowitz R; Muto M; Sheets E; Shulman LN
Cancer; 1998 Feb; 82(3):561-6. PubMed ID: 9452275
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
